Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine

PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the combination of weekly oxaliplatin × 4, weekly irinotecan × 4 and capecitabine Monday through Friday for 4 weeks of every 6 week cycle in patients with solid tumors; to determine the pharmacokinetic profile...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Chemother Pharmacol
Main Authors: Krishnamurthi, Smitha S., Brell, Joanna M., Hoppel, Charles L., Egorin, Merrill J., Weaver, Karen C., Li, Xiaolin, Ingalls, Stephen T., Zuhowski, Eleanor G., Schluchter, Mark D., Dowlati, Afshin, Cooney, Matthew M., Gibbons, Joseph, Overmoyer, Beth A., Ivy, S. Percy, Remick, Scot C.
格式: Artigo
語言:Inglês
出版: 2008
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4788493/
https://ncbi.nlm.nih.gov/pubmed/18414865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0754-2
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍